Biogen biosimilars and Spinraza fill MS void, but pipeline worries abound
admin 23rd October 2018 Uncategorised 0The burning question whenever Biogen unveils its numbers is this: Will its hot spinal muscular atrophy drug Spinraza be enough to cushion the blow from falling multiple sclerosis sales? For the third quarter, the answer was yes. But analysts still worry about Spinraza competition and an Alzheimer’s candidate awaiting key clinical data.
More: Biogen biosimilars and Spinraza fill MS void, but pipeline worries abound
Source: fierce